Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open‐label, single‐arm, noncomparative trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1743-7563|14|1|61-68

ISSN： 1743-7555

Source： ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol.14, Iss.1, 2018-02, pp. : 61-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 7, 2007-06 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 976-982

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III ‘Stop and Go' Study Results - A Turkish Oncology Group Trial

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 328-335

Karger

Access to resources Recommend Favorite

A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer

By Gelibter Alain J.   Gamucci Teresa   Pollera Camillo F.   Di Costanzo Francesco   Nuzzo Carmen   Gabriele Angela   Signorelli Carlo   Gasperoni Silvia   Ferraresi Virginia   Giannarelli Diana   Cognetti Francesco   Zeuli Massimo  

Current Medical Research and Opinion, Vol. 23, Iss. 9, 2007-09 ,pp. : 2117-2123

Informa Healthcare

Access to resources Recommend Favorite

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 129-135

Karger

Access to resources Recommend Favorite